Pfizer Inc (PFE)

PFE (NYSE:Drugs) EQUITY
$34.00
pos +0.00
+0.00%
Today's Range: 33.94 - 34.27 | PFE Avg Daily Volume: 25,073,100
Last Update: 03/24/17 - 4:00 PM EDT
Volume: 0
YTD Performance: 4.68%
Open: $0.00
Previous Close: $34.29
52 Week Range: $29.41 - $37.39
Oustanding Shares: 5,955,125,843
Market Cap: 204,201,265,156
6-Month Chart
TheStreet Ratings Grade for PFE
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 7 8 8 7
Moderate Buy 0 0 0 0
Hold 9 9 9 9
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 2.13 2.06 2.06 2.13
Latest Dividend: 0.32
Latest Dividend Yield: 3.73%
Dividend Ex-Date: 02/01/17
Price Earnings Ratio: 29.31
Price Earnings Comparisons:
PFE Sector Avg. S&P 500
29.31 29.30 30.30
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
4.68% 13.03% 7.97%
GROWTH 12 Mo 3 Yr CAGR
Revenue 8.10 0.00 0.01
Net Income 3.70 -0.40 -0.14
EPS 5.40 -0.60 -0.28
Earnings for PFE:
EBITDA 19.49B
Revenue 52.82B
Average Earnings Estimates
Qtr (03/17) Qtr (06/17) FY (12/17) FY (12/18)
Average Estimate $0.67 $0.65 $2.54 $2.78
Number of Analysts 5 4 9 8
High Estimate $0.72 $0.68 $2.58 $2.84
Low Estimate $0.63 $0.60 $2.45 $2.66
Prior Year $0.67 $0.64 $2.40 $2.54
Growth Rate (Year over Year) 0.30% 1.56% 5.97% 9.40%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
RMPIA
By

Bret Jensen

 | Mar 10, 2017 | 11:30 AM EST
Why the name is sagging, and what it will take to spur the sector higher.
RMPIA
By

Jim Cramer

 | Mar 7, 2017 | 2:00 PM EST
Drug companies are the latest targets/beneficiaries.
RMPIA
By

Jim Cramer

 | Mar 6, 2017 | 6:50 AM EST
Bull market number one, perhaps of all time: the financials.
By

Jim Cramer

 | Feb 28, 2017 | 11:30 AM EST
Let's recognize that some moves are simply related to bonds, which are in the grips of a bizarre developed-world shortage.
RMPIA
By

Bret Jensen

 | Feb 22, 2017 | 10:00 AM EST
These two large-cap drug giants should be core parts of any well-diversified portfolio.
RMPIA
By

Bret Jensen

 | Feb 15, 2017 | 11:30 AM EST
M&A activity is in a serious upswing, and here are some names to watch.
RMPIA
By

Jim Cramer

 | Feb 9, 2017 | 6:12 AM EST
Static doesn't work in this industry. Pipelines work.
RMPIA
By

Jim Cramer

 | Feb 8, 2017 | 11:24 AM EST
Jim Cramer compares Allergan's growth to other pharma stocks.
By

Bret Jensen

 | Jan 29, 2017 | 2:00 PM EST
The Actelion buyout opens the way for other deals.
By

Bret Jensen

 | Jan 27, 2017 | 11:00 AM EST
The Actelion buyout opens the way for other deals.

REAL MONEY PRO'S BEST IDEAS

News Breaks

Powered by
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.